Skip to main content
Clinical Trials/JPRN-UMIN000001908
JPRN-UMIN000001908
Unknown
未知

A prospective cohort study of blood transfusion-dependent chronic anemia in Akita - Cohort study of transfusion-dependent anemia

Akita University School of Medicine, Department of Medicine, Division of Hematology, Nephrology and Rheumatology0 sites100 target enrollmentMay 1, 2009

Overview

Phase
未知
Intervention
Not specified
Conditions
Chronic anemia dependent on red cell transfusion
Sponsor
Akita University School of Medicine, Department of Medicine, Division of Hematology, Nephrology and Rheumatology
Enrollment
100
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 1, 2009
End Date
March 1, 2014
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Akita University School of Medicine, Department of Medicine, Division of Hematology, Nephrology and Rheumatology

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Patients who are difficult to visit the outpatient clinic on a regular basis.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Randomised trial of a blood transfusion policy after fracture of the proximal femur (hip fracture)Surgery: Blood transfusionSurgeryBlood transfusion
ISRCTN61328173Department of Health (UK)
Active, not recruiting
Phase 1
ASubjects treated with gene therapy drug products in a bluebird bio-sponsored study will be invited to participate in this long-term follow-up study to monitor the safety and efficacy of the drug products. To date, subjects in this study have been treated with bluebird bio gene therapy drug products developed to treat beta-thalassaemia majorMedDRA version: 23.1Level: LLTClassification code 10082045Term: Beta-thalassemia traitSystem Organ Class: 100000004850Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2013-002245-11-GRbluebird bio, Inc.94
Not yet recruiting
Not Applicable
Blood Donor and Recipient Long-Term Outcome StudyTransfusion of whole blood, erythrocyte concentrate, thrombocyte concentrate and massive transfusion (G-DRG OPS 8-800)Frozen plasma administration (OPS 8.812.6-8.812.8)Prothrombin concentrate administration (OPS 8-812.5)Fibrinogen administration (OPS 8-810.j)mechanical autotransfusion (OPS 8-803.2-3) Other blood products
DRKS00034405Goethe Universität Frankfurt, Universitätsklinikum, Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie1,000,000
Completed
Phase 2
Evaluation of blood transfusion intervals in patients with ß-thalassemia major before and after administration of hydroxyurea
IRCT20180707040371N1Gorgan University of Medical Sciences20
Recruiting
Not Applicable
Effect of Blood Transfusion in Covid-19Respiratory status of patients with Covid 19.COVID-19, virus identifiedU07.1
IRCT20201003048904N1Boushehr University of Medical Sciences40